The Association Between Positive Amyloid-PET and Cognitive Decline Is Not Always Supportive of Alzheimer's Disease: Suggestions from a Case Report

Overview

Journal J Alzheimers Dis Rep

Publisher IOS Press

Date 2024 Feb 26

PMID 38405347

Authors

Gemma Lombardi

Valentina Berti

Andrea Ginestroni

Benedetta Nacmias

Sandro Sorbi

Affiliations

Soon will be listed here.

Abstract

Amyloid-β deposition is the pathological hallmark of both cerebral amyloid angiopathy and Alzheimer's disease dementia, clinical conditions that can share cognitive decline and positive Amyloid-PET scan. A case is reported involving an 82-year-old Italian female who presented initially a memory deficit, later transient focal neurologic episodes, and finally two symptomatic lobar intracerebral hemorrhages. In light of these events, MRI and PET imaging findings, acquired before cerebral hemorrhages, are reconsidered and discussed, highlighting the utility of Amyloid-PET in supporting an diagnosis of cerebral amyloid angiopathy.

References

Boulouis G, Charidimou A, Jessel M, Xiong L, Roongpiboonsopit D, Fotiadis P . Small vessel disease burden in cerebral amyloid angiopathy without symptomatic hemorrhage. Neurology. 2017; 88(9):878-884. PMC: 5331873. DOI: 10.1212/WNL.0000000000003655. View

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

Lummel N, Wollenweber F, Demaerel P, Bochmann K, Malik R, Opherk C . Clinical spectrum, underlying etiologies and radiological characteristics of cortical superficial siderosis. J Neurol. 2015; 262(6):1455-62. DOI: 10.1007/s00415-015-7736-1. View

Mosconi L, McHugh P . FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?. Q J Nucl Med Mol Imaging. 2011; 55(3):250-64. PMC: 3290913. View

Chang Y, Liu J, Wang L, Li X, Wang Z, Lin M . Diagnostic Utility of IntegratedC-Pittsburgh Compound B Positron Emission Tomography/Magnetic Resonance for Cerebral Amyloid Angiopathy: A Pilot Study. Front Aging Neurosci. 2021; 13:721780. PMC: 8660657. DOI: 10.3389/fnagi.2021.721780. View

Raposo N, Sonnen J . Amyloid-PET in cerebral amyloid angiopathy: Detecting vascular amyloid deposits, not just blood. Neurology. 2017; 89(14):1437-1438. DOI: 10.1212/WNL.0000000000004548. View

Chan E, Bonifacio G, Harrison C, Banerjee G, Best J, Sacks B . Domain-specific neuropsychological investigation of CAA with and without intracerebral haemorrhage. J Neurol. 2023; 270(12):6124-6132. PMC: 10632296. DOI: 10.1007/s00415-023-11977-8. View

Bergeret S, Queneau M, Rodallec M, Landeau B, Chetelat G, Hong Y . Brain Glucose Metabolism in Cerebral Amyloid Angiopathy: An FDG-PET Study. Stroke. 2021; 52(4):1478-1482. DOI: 10.1161/STROKEAHA.120.032905. View

Malhotra K, Theodorou A, Katsanos A, Zompola C, Shoamanesh A, Boviatsis E . Prevalence of Clinical and Neuroimaging Markers in Cerebral Amyloid Angiopathy: A Systematic Review and Meta-Analysis. Stroke. 2022; 53(6):1944-1953. DOI: 10.1161/STROKEAHA.121.035836. View

10.

Shoamanesh A, Martinez-Ramirez S, Oliveira-Filho J, Reijmer Y, Falcone G, Ayres A . Interrelationship of superficial siderosis and microbleeds in cerebral amyloid angiopathy. Neurology. 2014; 83(20):1838-43. PMC: 4240429. DOI: 10.1212/WNL.0000000000000984. View

11.

Jang H, Jang Y, Kim H, Werring D, Lee J, Choe Y . Clinical significance of amyloid β positivity in patients with probable cerebral amyloid angiopathy markers. Eur J Nucl Med Mol Imaging. 2019; 46(6):1287-1298. DOI: 10.1007/s00259-019-04314-7. View

12.

Na H, Park J, Kim J, Kim H, Kim S, Werring D . Cortical superficial siderosis: a marker of vascular amyloid in patients with cognitive impairment. Neurology. 2015; 84(8):849-55. DOI: 10.1212/WNL.0000000000001288. View

13.

Farid K, Charidimou A, Baron J . Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update. Neuroimage Clin. 2017; 15:247-263. PMC: 5435601. DOI: 10.1016/j.nicl.2017.05.002. View

14.

Lombardi G, Pupi A, Bessi V, Polito C, Padiglioni S, Ferrari C . Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences. J Alzheimers Dis. 2020; 77(1):203-217. DOI: 10.3233/JAD-200119. View

15.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

16.

Johnson K, Gregas M, Becker J, Kinnecom C, Salat D, Moran E . Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007; 62(3):229-34. DOI: 10.1002/ana.21164. View

17.

Lehmann M, Koedam E, Barnes J, Bartlett J, Ryan N, Pijnenburg Y . Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiol Aging. 2011; 33(3):627.e1-627.e12. PMC: 3657170. DOI: 10.1016/j.neurobiolaging.2011.04.003. View

18.

Bergeret S, Queneau M, Rodallec M, Curis E, Dumurgier J, Hugon J . [ F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer's disease. Eur J Neurol. 2021; 28(5):1511-1519. DOI: 10.1111/ene.14743. View

19.

Szidonya L, Nickerson J . Cerebral Amyloid Angiopathy. Radiol Clin North Am. 2023; 61(3):551-562. DOI: 10.1016/j.rcl.2023.01.009. View

20.

Charidimou A, Farid K, Tsai H, Tsai L, Yen R, Baron J . Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry. 2017; 89(4):410-417. DOI: 10.1136/jnnp-2017-316851. View